Journals / Tıp Araştırmaları Dergisi / 2010 / Cilt: 8 - Sayı: 3

Clinical use of bone scintigraphy

Kemik sintigrafisin klinik kullanımı

Pages
210–220
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Radionuclide bone imaging will likely remain a popular and important imaging modality for years to come.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bone scintigraphy with technetium-99m (Tc-99m) labeled diphosphonates is one of the most frequently performed of all radyonuclide procedures.
📊
Key Findings & Data:Bone metastases usually appear as multiple foci of increased activity, although they occasionally manifest as areas of decreased uptake.
💡
Conclusion & Impact:Radionuclide bone imaging will likely remain a popular and important imaging modality for years to come.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Bone scintigraphy with technetium-99m (Tc-99m) labeled diphosphonates is one of the most frequently performed of all radyonuclide procedures. Radionuclide bone imaging is not specific, but its excellent sensitivity makes it useful in screening for many pathologic conditions. Moreover, some conditions that are not clearly depicted on anatomic images can be diagnosed with bone scintigraphy. Bone metastases usually appear as multiple foci of increased activity, although they occasionally manifest as areas of decreased uptake. Traumatic processes can often be detected, even radiographic findings are negative. A combination of focal hyperperfusion, focal hyperemia, and focally increased bone uptake is virtually diagnostic for osteomyelitis in patients with nonviolated bone. Bone scintigraphy is also useful for evaluating disease extent in Paget disease and for localizing avascular necrosis in patients with negative radiographs. Radionuclide bone imaging will likely remain a popular and important imaging modality for years to come.

Özet

Teknesyum 99m (Tc-99m) difosfanatlarla yapılan kemik sintigrafisi radyonüklid görüntülemeler içinde en sık kullanılan tetkik olma özelliğine sahiptir. Radyonüklid kemik görüntüleme spesifik değildir ancak sensitivitesi çok yüksek olduğundan çoğu patolojik durumda diğer görüntüleme yöntemlerinden daha faydalıdır. Anatomik görüntüleme modaliteleri ile kesin karar verilemeyen çoğu durumda, kemik sintigrafisi ile tanı koyulabilir. Kemik metastasları çoğunlukla multiple fokal artmış aktivite tutulumu olarak izlenmesine rağmen nadirde olsa radyoaktivite tutulumunun azalması şeklinde de görülebilir. Travmatik durumlarda radyografik bulgular negatif olsa bile sintigrafik bulgu saptanabilir. Lokal perfüzyon, hiperemi ve artmış radyoaktivite uptake'inin birlikte bulunması şüpheli hastalarda osteomiyelit tanısı konulmasında faydalıdır. Kemik sintigrafisi, paget hastalığının yaygınlığının değerlendirilmesinde ve radyografik olarak belirlenemeyen avasküler nekroz hastalarına tanı koyulmasında faydalıdır. Radyonüklid kemik görüntüleme ucuz, kolay uygulanabilir ve tüm vücut kemiklerinin değerlendirme imkanı vermesi sebebiyle günümüzde en popüler görüntüleme yöntemlerinden olmaya devam etmektedir.

🔖

Cite This Article

AYDOĞAN, F., ÖZDEN, R. (2010). Clinical use of bone scintigraphy. Tıp Araştırmaları Dergisi, Cilt: 8 - Sayı: 3, 210–220. https://ajindex.com/articles/361851

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ziessman H, O' Malley J, Thrall J. Nuclear Medicine: The Requisites 3rd ed. Philadelphia, U.S. 2006; 113-129
  2. Wilson M, Textbook of Nuclear Medicine. Philadelphia, U.S. 1998; 4-21
  3. McAfee JG, Reba RC, Majd M. The musculoskeletal system. In: Wagner HN Jr, Szabo Z, Buchanan JW, eds. Principles of nuclear medicine. 2nd ed. Philadelphia, Pa: Saunders, 1995; 986–1012
  4. Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci. 2009; 24(2): 275-280
  5. Sanders TG, Parsons TW. Radiographic imaging of musculoskeletal neoplasia. Cancer Control. 2001 8(3): 221-231 6. Hamaoka T, Madewell J. E, Podoloff D. A, Hortobagyi G.N, Ueno N.T Bone Imaging in Metastatic Breast Cancer Journal of Clinical Oncology 2004; 22 (14- July 15): 2942-2953 7. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop Clin North Am 2000; 31:515–528
  6. Charron M, Brown M, Diagnostic Nuclear Medicine. In: Sandler M, 4th ed. Philadelphia, U.S. 2003; 414- 420
  7. Buckley O, O'Keeffe S, Geoghegan T, Lyburn ID, Munk PL, Worsley D, Torreggiani WC. 99mTc bone scintigraphy superscans: a review. Nucl Med Commun. 2007 Jul;28(7):521-7
  8. Mari C, Catafau A, Carrio I. Bone scintigraphy and metabolic disorders. Q J Nucl Med 1999; 43: 259–267
  9. Cook GJ, Gnanasegaran G, Chua S. Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumors. Semin Nucl Med. 2010 Jan;40(1):52-61
  10. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001; 45:27–37
  11. Römer W, Nömayr A, Uder M, Bautz W, Kuwert T. SPECT-Guided CT for Evaluating Foci of Increased Bone Metabolism Classified as Indeterminate on SPECT in Cancer Patients J Nucl Med. 2006 Jul;47(7):1102-6. Erratum in: J Nucl Med. 2006 Oct;47(10):1586
  12. Sapir EE. Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J Nucl Med 2005; Vol. 46 (8): 1356-1367 15. Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009 Nov;39(6):408-15
  13. Stokkel MPM, Valdes Olmos RA, Hoefnagel CA, Richel DJ. Tumor and therapy associated abnormal changes on bone scintigraphy: ol